Prenatal Exposure to Mycophenolate Mofetil: An Updated Estimate

Journal of Obstetrics and Gynaecology Canada

Volumn 32, Issue 8, 2010, Pages 794-797

  Klieger Grossmann, Chagit ^a   Chitayat, David ^b   Lavign, Sharon ^c   Kao, Kelly ^d   Garcia Bournissen, Facundo ^a   Quinn, Dee ^e   Luo, Vicky ^a   Sermer, Mathew ^b   Riordan, Sara ^e   Laskin, Carl ^b   Matok, Ilan ^f   Gorodischer, Rafael ^f   Chambers, Christina ^d   Levi, Amalia ^f   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of Tuscon   (United States)

^f BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Birth defects; Immunosuppressant; Inflammatory bowel diseases; Mycophenolate mofetil; Pregnancy; Systemic lupus erythematosus

Indexed keywords

MYCOPHENOLATE MOFETIL; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTICLE; CLEFT PALATE; CLINICAL ARTICLE; CONGENITAL DIAPHRAGM HERNIA; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; EMBRYO DEVELOPMENT; FEMALE; FOLLOW UP; HUMAN; INDUCED ABORTION; LIVE BIRTH; MALE; MICROTIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RISK ASSESSMENT; SPONTANEOUS ABORTION; TERATOGENICITY; PREGNANCY; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79953331677     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34622-9     Document Type: Article

References (18)

1. Product information. Cell Cept. Roche Pharmaceuticals 2007.
2. Armenti V.T., Mortiz M.J., Cardonick E.H., Davison J.M. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs 2002, 62:2361-2375.
3. Ginzler E.M., Dooley M.A., Aranow C., Kim M.Y., Buyon J., Merrill J.T., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
4. US Food and Drug Administration MedWatch the FDA safety information and adverse event reporting program. Cellcept (mycophenolate mofetil) October 2007, 2219-2228. [Update 11/27/2007]. Available at: Accessed June 8, 2010. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152095.htm.
5. Henshaw S.K. Unintended pregnancy in the United States. Fam Plann Perspect 1998, 30:24-29.
6. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
7. Tendron A., Gouyon J.B., Decramer S. In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 2002, 17:121-130.
8. Pergola P.E., Kancharla A., Riley D.J. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation 2001, 71:994-997.
9. Le Ray C., Coulomb A., Elefant E., Frydman R., Audibert F. Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 2004, 103:1091-1094.
10. Perez-Aytes A., Ledo A., Boso V., Saenz P., Roma E., Poveda J.L., et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype?. Am J Med Genet A 2008, 146A:1-7.
11. Huang S.Y., Chueh H.Y., Shaw S.W., Shih J.C., Cheng P.J. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. Am J Obstet Gynecol 2008, 199:e6-e8.
12. Andrade Vila J.H., da Silva J.P., Guilhen C.J., Baumgratz J.F., da Fonseca L. Even low dose of mycophenolate mofetil in a mother recipient of heart transplant can seriously damage the fetus. Transplantation 2008, 86:369-370.
13. Schoner K., Steinhard J., Fiqiel J., Rehder H. Severe facial clefts in acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil?. Obstet Gynecol 2008, 111:483-486.
14. Ang G.S., Simpson S.A., Reddy A.R. Mycophenolate mofetil embryopathy may be dose and timing dependent. Am J Med Genet A 2008, 146A:1963-1966.
15. Anderka M.T., Lin A.E., Abuelo D.N., Mitchell A.A., Rasmussen S.A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009, 149A:1241-1248.
16. Parisi M.A., Zayed H., Slavotinek A.M., Rutledge J.C. Congenital diaphragmatic hernia and microtia in a newborn with mycophenolate mofetil (MMF) exposure: phenocopy for Fryns syndrome or broad spectrum of teratogenic effects?. Am J Med Genet A 2009, 149A:1237-1240.
17. Sifontis N.M., Coscia L.A., Constantinescu S., Lavelanet A.F., Mortiz M.J., Armenti V.T. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation 2006, 82:1698-1702.
18. Bar-Oz B., Moretti M., Mareels G., Van Tittelboom T., Koren G. Reporting bias in retrospective ascertainment of drug induced embryopathy. Lancet 1999, 354:1700-1701.